

Editorial : Case Reports in Respiratory Pharmacology 2022

Przemyslaw Zdziarski^{1*}, Luisa Ricciardi², Roberto Paganelli³

¹Lower Silesian Oncology Center, Poland, ²Department of Clinical and Experimental Medicine, University of Messina, Italy, ³Saint Camillus International University of Health and Medical Sciences, Italy

Submitted to Journal:
Frontiers in Pharmacology

Specialty Section:
Respiratory Pharmacology

Article type:
Editorial Article

Manuscript ID:
1242273

Received on:
18 Jun 2023

Journal website link:
www.frontiersin.org

In review

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Author contribution statement

PZ and RP have been involved in drafting the manuscript; PZ revising it critically for important intellectual content. RP proofread and improved the manuscript for brevity. RP and LR have revised, read and approved the final manuscript.

Keywords

respiratory pharmacology, case study, Patient-Centered Care, SARS-CoV-2, corticosteroids, Pharmacovigilance, Eosinophilic granulomatosis with polyangiitis (EGPA), off-label

Contribution to the field

Firstly, article shows the difference of case studies and their important (often underestimated) place in the literature. These descriptions represent unique examples of personalized medicine in areas where, since standard guidelines are missing or not applicable (Table 1). Editorial article is a summary of TOPIC and showing the interdisciplinarity of pulmonary pharmacology on the example of publications included in the collection.

Editorial : Case Reports in Respiratory Pharmacology 2022

1 **Przemyslaw Zdziarski¹, Luisa Ricciardi², Roberto Paganelli³,**

2 ¹Department of Clinical Immunology and Pulmonary Disease, Lower Silesian Oncology,
3 Pulmonology and Hematology Centre, Wroclaw, Poland

4 ² Department of Clinical and Experimental Medicine, University of Messina, Italy

5 ³ Internal Medicine, Saint Camillus International University of Medical and Health Sciences, Rome,
6 Italy

7 *** Correspondence:**

8 Przemyslaw Zdziarski
9 prion@interia.eu

10 **Keywords: respiratory pharmacology, case study, patient-centered care, SARS-CoV-2,**
11 **corticosteroids, pharmacovigilance, Eosinophilic Granulomatosis with Polyangiitis (EGPA),**
12 **off-label**

13 Despite the separation of pulmonology from other disciplines, the diseases of the respiratory
14 system may present systemic symptoms and their treatment cause systemic effects. Tuberculosis and
15 SARS, atopic asthma, lymphoid interstitial pneumonia, Eosinophilic Granulomatosis with
16 Polyangiitis (EGPA), and immunoendocrinopathy, described in our collection, are good examples.
17 On the other hand, this makes construction of cohort studies more difficult. Lessons from individual
18 clinical cases with a comprehensive, holistic approach can be all the more instructive, especially in
19 rare diseases or long- term observation (Table 1) (Tenny et al., 2022).

20 This Research Topic included four high-quality case reports published last year in Frontiers in
21 Pharmacology, highlighting aspects of clinical pharmacology of drugs used for the treatment of
22 respiratory diseases. The description of the diagnostic work-up, clinical assessment, therapeutic
23 measures and monitoring of outcomes of single cases or small series of patients is a very useful
24 adjunct to large clinical trials, particularly when evaluating uncommon conditions, such as those
25 presented here: muscle paralysis, myxedema, or the non-standard (off-label) use of approved drugs
26 (e.g. ramatroban and benralizumab in our series, see below). These descriptions represent examples
27 of personalized medicine, since standard guidelines are missing or not applicable (Table 1).

28 Wang et al. (<https://doi.org/10.3389/fphar.2022.900701>) described how overlooking untreated
29 hypothyroidism on hospital admission may lead to severe respiratory distress. The role of
30 hypothyroidism in cardiology is well known (Kagansky et al., 2023). Although cardiomegaly
31 (primarily due to pericardial effusion) is a typical sign of myxedema, it develops slowly, rarely
32 causing hemodynamic distress (Glenn and Braunstein, 2022); therefore, it may go unnoticed for a
33 long time. Currently, when subclinical hypothyroidism is diagnosed, its late-stage forms, such as
34 myxedema, are often underestimated, because dyspnea suggests cardiopulmonary disorders. In the
35 study, a delayed and inadequate initial treatment with low T4 dose was adopted, thus prolonging
36 edema and causing multi-organ failure. This report also advocates the use of glucocorticoid treatment
37 in addition to adequate dose of i.v. levothyroxine (Glenn and Braunstein, 2022), since T4 increases
38 glucocorticoid receptors expression, facilitating steroid anti-edematous effects through an increased

diuretic action (Liu et al., 2006). The inclusion of steroids in the treatment may be beneficial by interacting with the hypothalamus-pituitary- adrenal axis (decrease of ACTH and corticotropin-releasing hormone - direct inhibitor of TSH secretion), as well as by inhibiting pathogenic IgG autoantibodies synthesis (Zdziarski et al., 2022).

Pulmonary infections, especially with viral pathogens, are considered among the leading causes of mortality, fast pandemic spread and high economic costs. The efficacy of Ramatroban, a dual Thromboxane A2 and Prostaglandin D2 receptor antagonist, in COVID-19 pneumonia was described by Ogletree et al. (<https://doi.org/10.3389/fphar.2022.904020>) in four cases whose improvement avoided hospitalization despite initial respiratory distress. The possible mechanisms ranged from improved ventilation-reperfusion matching, to restored type 1 Interferon production at epithelial surfaces. Moreover, no long-term sequelae of COVID-19, such as lung fibrosis (Kimura et al., 2023), were observed.

The treatment of bacterial respiratory infections in the era of antibiotic resistance is complicated also by adverse drug reactions (ADRs). An estimated 5–25% of hospital admissions are due to ADRs, and 6–15% of hospitalized patients experience serious ADRs (source VigAccess – Adverse Drug Reaction (ADR) Database - World Health Organization's free database), causing significant prolongation of hospital stay (Ramirez et al. 2022). Nin et al (<https://doi.org/10.3389/fphar.2022.963140>) reported respiratory muscle paralysis in a transplant patient treated with Polymixin B, a rare but possibly fatal complication of this drug, known for its potential nephrotoxicity (Sorli et al., 2013) and risk of anaphylaxis (Zhan et al., 2019). This life threatening ADR should alert doctors treating patients with renal dysfunctions.

A fourth case report dealt with the treatment of a patient with EGPA experiencing severe asthma (<https://doi.org/10.3389/fphar.2022.858344>). The patient was a difficult case, diagnosed only after several episodes of pericarditis, with anti-neutrophil cytoplasmic antibodies (ANCA) resulting negative, and also considering her young age (22 yrs). Since oral corticosteroids had minimal effects, she was treated with an anti-IL-5R, benralizumab, not approved for EGPA (off-label), at variance with the anti-IL5 monoclonal mepolizumab (Koike et al., 2023). A rapid benefit was observed, but the interest of this case lies in the recognition of the pitfalls when diagnosing unusual presentations: also ANCA-negative patients with early-onset asthma should be investigated for EGPA in future studies.

These four reports illustrate some important points in the field, such as the use of corticosteroids in severe hypothyroidism, the possible use of benralizumab in systemic vasculitis, and of ramatroban in COVID-19 (Kupczyk and Kuna, 2017; Al-Kuraishy et al., 2023). They also show persisting shadows in the pharmacovigilance of colistin, and pitfalls in diagnosing emergency admissions, such as overlooking untreated hypothyroidism.

Unusual clinical aspects and responses to treatment in this series may help personalized and more rational pharmacological therapy of respiratory diseases, with the identification of pertinent outcomes. The case studied may help clinicians choose therapeutic options in other rare conditions.

1 Tables

Table 1. Complementarity of cohort and case studies.

Area \ Studies	Cohort	Case reports	Example (from the collection)
Study of rare diseases or rare constellations	impractical	useful	<i>Wang et al.</i> <i>Nin et al.</i>
Application in the clinic and treatment strategy	indirect	direct	<i>Ogletree et al.</i> <i>Ricciardi et al.</i>
Nature of the study	prospective	retrospective	all listed
Comprehensive description of natural history of disease	No	Yes	<i>Wang et al.</i> (myxedema) <i>Ricciardi et al.</i> (EGPA)
Time-line of therapeutic regimens with many drugs	No	Yes	<i>Wang et al.</i> <i>Ricciardi et al.</i>
Risk factors analyzed	limited	multiple	<i>Ricciardi et al.</i> (population at risk)
Cause-effect relationship (association between exposure and an event)	Statistical correlation	Temporal, pathogenetic links	<i>Ogletree et al.</i> <i>Nin et al.</i> <i>Ricciardi et al.</i> (circumstantial)
Adverse drug reaction and causality assessment*	Must be planned (usually predictable ARDs)	Simple (e.g. based on drug withdrawal)	<i>Nin et al.</i>

The table shows the areas of knowledge reserved for cohort or case studies, indicating strengths/weaknesses as well as examples within the article collection (Frontiers in Pharmacology Research Topic). Case studies give the possibility of collecting all data (for patient-centered care), instead of those used for planning prospective studies. *Unpredictable side effects (also beneficial) are the issue that cannot be directly planned in cohort studies.

2 FOOTNOTES

2.1 Abbreviations:

Adverse drug reactions (ADRs)

Acute Respiratory Distress (ARD)

Adrenocorticotrophic hormone (ACTH or corticotropin)

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

91 Tidal volume, TV

92 **2.2 Conflict of Interest**

93 *The authors declare that the research was conducted in the absence of any commercial or financial*
94 *relationships that could be construed as a potential conflict of interest.*

95 **2.3 Author Contributions**

96 PZ and RP have been involved in drafting the manuscript; PZ revising it critically for
97 important intellectual content. RP and LR have revised, read and approved the final
98 manuscript.

99 **2.4 Funding**

100 Not applicable

101 **3 References**

102 Al-Kuraishy, H. M., Al-Gareeb, A. I., Saad, H. M. & Batiha, G. E. 2023. The effect of ramatroban on
103 cytokine and thrombotic storms in Covid-19. *Inflammopharmacology*, 31, 543-545.

104 Glenn D. Braunstein MD Hypothyroidism (Myxedema) – in – Merck Manual Professional version,
105 Merck & Co, Inc., Rahway, NJ, USA . Sep 2022

106 Kagansky, D., Or, K., Elkan, M., Koren, S. & Koren, R. 2023. The effect of over- and
107 undertreatment of hypothyroidism on hospitalization outcomes of patients with decompensated heart
108 failure. *J Investig Med*, 10815589231162542.

109 Kimura, R. H., Sharifi, H., Shen, B., Berry, G. J. & Guo, H. H. 2023. alpha(v)beta(6) Integrin
110 Positron Emission Tomography of Lung Fibrosis in Idiopathic Pulmonary Fibrosis and Long-
111 COVID. *Am J Respir Crit Care Med*.

112 Koike, H., Nishi, R., Yagi, S., Furukawa, S., Fukami, Y., Iijima, M. & Katsuno, M. 2023. A Review
113 of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis. *Adv Ther*, 40, 25-40.

114 Kupczyk, M. & Kuna, P. 2017. Targeting the PGD(2)/CRTH2/DP1 Signaling Pathway in Asthma
115 and Allergic Disease: Current Status and Future Perspectives. *Drugs*, 77, 1281-1294.

116 Liu, C., Chen, H., Zhou, C., Ji, Z., Liu, G., Gao, Y., Tian, L., Yao, L., Zheng, Y., Zhao, Q. & Liu, K.
117 2006. Potent potentiating diuretic effects of prednisone in congestive heart failure. *J Cardiovasc*
118 *Pharmacol*, 48, 173-6.

119 Ramírez E, González-Munoz M, Kulkarni C and de Abajo FJ (2022) Editorial: Reducing the Harm of
120 Medication–Recent Trends in Pharmacovigilance. *Front. Pharmacol.* 13:964125. doi:
121 10.3389/fphar.2022.964125

122 Sorli, L., Luque, S., Grau, S., Berenguer, N., Segura, C., Montero, M. M., Alvarez-Lerma, F.,
123 Knobel, H., Benito, N. & Horcajada, J. P. 2013. Trough colistin plasma level is an independent risk
124 factor for nephrotoxicity: a prospective observational cohort study. *BMC Infect Dis*, 13, 380.

- 125 Zdziarski P, Paściak M and Gamian A (2022) Microbiome Analysis and Pharmacovigilance After
126 Inhaled Glucocorticoid: Oral Dysbiosis With the Isolation of Three Rothia Species and Subsequent
127 Sjögren's Syndrome. Front. Pharmacol. 13:636180. doi: 10.3389/fphar.2022.636180
- 128 Zhan, Y., Ma, N., Liu, R., Wang, N., Zhang, T. & He, L. 2019. Polymyxin B and polymyxin E
129 induce anaphylactoid response through mediation of Mas-related G protein-coupled receptor X2.
130 Chem Biol Interact, 308, 304-311.

In review